| [1] |
1 Sun W, Haller DG. Recent advances in the treatment of gastric cancer[J]. Drugs, 2001, 61(11): 1545-1551.
2 Frei E. Clinical cancer research: an embattled species[J]. Cancer,1982, 50(10): 1979-1992.
3 季加孚. 胃癌外科的现状与发展趋势[J].中国普外基础与临床杂志,2006,13(1):1-3.
4 金懋林.新辅助化疗在胃癌治疗中的作用[J].外科理论与实践,2000,5(3):140-142.
5 Wilke H, Preusser P, Fink U,et al. Preoperative chemotherapy inlocally advanced and nonresectable gastric cancer: a phase Ⅱ studywith etoposide, doxorubicin, and cisplatin[J]. J Clin Oncol, 1989, 7(9):1318-1326.
6 Kollmannsberger C, Quietzsch D, Haag C, et al. A phase Ⅱ studyof paclitaxel, weekly, 24 -hour continuous infusion 5 -fluorouracil,folinic acid and cisplatin in patients with advanced gastric cance[J].Br J Cancer, 2000, 83(4): 458-462.
7 Lowy AM, Mansfield PF, Leach SD, et al. Response to neoadjuvantchemotherapy best predicts survival after curative resection of gastriccancer[J]. Ann Surg,1999, 229(3): 309-312.
8 Plukker JT, Mulder NH,Sleijfer DT, et al. Chemotherapy andsurgery for locally advanced cancer of the cardia and fundus: phaseⅡ study with methotrexate and 5-fluorouracil[J]. Br J Surg, 1991,78(8): 955-958.
9 Mai M,TakahashiY, Fujimoto T, et al. Neoadjuvant chemotherapyfor far-advanced gastric carcinoma[J]. Gan To Kagaku Ryoho,1994, 21(4): 431-439.
10 Yoshikawa T, Tsuburaya A, Kobayashi O, et al. Neoadjuvantchemotherapy with a combination of irinotecan and cisplatin inadvanced gastric cancer-a case report[J]. Hepatogastroenterology,2000, 47(36): 1575-1578.
11 Newman E, Marcus SG, Potmesil M, et al. Neoadjuvantchemotherapy with CPT-11 and cisplatin downstages locally ad-vanced gastric cancer[J]. J Gastrointest Surg, 2002, 6(2): 212-223.
12 Ott K, Sendler A,Becker K, et al. Neoadjuvant chemotherapy withcisplatin, 5-FU,and leucovorin(PLF) in locally advanced gastriccancer: a prospective phase Ⅱ study[J]. Gastric Cancer, 2003, 6(3):159-167.
13 陈世壮,方晓敏,刘静,等.TPLF 方案在局部进展期胃癌新辅助化疗中的应用[J].临床肿瘤学杂志,2006,11(10):765-767.
14 杨喆,王治国.多西他赛联合顺铂、 氟尿嘧啶和亚叶酸的新辅助化疗方案治疗不能切除进展期胃癌的疗效观察[J].中国癌症杂志,2006,16(5):346-350.
15 陈晓耕,林志彬.局部晚期胃癌的新辅助化疗的临床研究[J].齐齐哈尔医学院学报,2006,27(11):1297-1299.
16 王建芳,田景琦,吕杰青.35 例局部晚期胃癌EOLF 方案新辅助化疗临床观察[J].肿瘤学杂志,2006,12 (3):220-221.
17 方育,王亚军,李非,等.奥沙利铂联合甲酰四氢叶酸钙和氟尿嘧啶新辅助化疗方案治疗进展期胃癌的研究[J].中华胃肠外科杂志,2006,9(6):510-512.
18 谷小虎,赵宜良.FOLFOX 方案行胃癌新辅助化疗38 例疗效观察[J].实用肿瘤学杂志,2006,20(6):538-540.
19 林丽珠,周岱翰,郑心婷.洛铂联合氟尿嘧啶和甲酰四氢叶酸治疗晚期耐药胃癌结直肠癌疗效观察[J].中国肿瘤临床,2007,34(5):46-48.
20 沈琳,金懋林,张晓东,等.奥沙利铂联合表阿霉素5-FU/CF治疗晚期胃癌的临床研究[J].中国肿瘤临床,2005,32(8):52-55.
21 谢忠,谢杰荣,温继育.草酸铂或顺波联合氟尿嘧啶及醛氢叶酸治疗晚期胃癌的对比研究[J].中国肿瘤临床,2006,33(18):21-23.
22 孙辉,殷季良,应江山.庚铂一线治疗不能手术胃癌217例临床报告[J].中国肿瘤临床,2005,32(17):52-55.
23 Napieralski R, Ott K, Kremer M, et al. Combined GADD45A andthymidine phosphorylase expression levels predict response andsurvival of neoadjuvant-treated gastric cancer patients[J]. ClinCancer Res, 2005, 11(8): 3025-3031.
24 Ott K, Vogelsang H, Marton N, et al. The thymidylate synthasetandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastriccancer[J]. Int J Cancer, 2006, 119(12): 2885-2894.
|
下载:
